Exploiting the "Hot-Spots" of Hsp70 - Bim Protein - Protein Interaction to Optimize the 1-Oxo-1 H-phenalene-2,3-dicarbonitrile Analogues as Specific Hsp70 - Bim Inhibitors

  • J Med Chem. 2023 Dec 14;66(23):16377-16387. doi: 10.1021/acs.jmedchem.3c01783.
Ziqian Wang  1 ,  Hong Zhang  1 ,  Xin Li  1 ,  Yang Song  2 ,  Yuying Wang  3 ,  Zhiyuan Hu  3 ,  Qishuang Gao  1 ,  Maojun Jiang  1 ,  Fangkui Yin  1 ,  Linjie Yuan  1 ,  Jingjing Liu  3 ,  Ting Song  1 ,  Shaohua Lu  1 ,  Guanghong Xu  1 ,  Zhichao Zhang  1
Affiliations
  • 1. School of Chemistry, Dalian University of Technology, Dalian, Liaoning 116024, China.
  • 2. Department of Hematology, Central Hospital of Dalian University of Technology, Dalian, Liaoning 116023, China.
  • 3. School of Bioengineering, Dalian University of Technology, Dalian, Liaoning 116024, China.
PMID: 38011535 DOI: 10.1021/acs.jmedchem.3c01783
Abstract

Selectively targeting the cancer-specific protein-protein interaction (PPI) between HSP70 and Bim has been discovered as a promising strategy for treating chronic myeloid leukemia (CML). The first HSP70-Bim PPI inhibitor, S1g-2, has been identified to overcome the on-target toxicity of known HSP70 inhibitors when it induces Apoptosis of CML cells. Herein, we carried out a hit-to-lead optimization of S1g-2, yielding S1g-10, which exhibited a 10-fold increase in HSP70/Bim suppressing potency. Furthermore, S1g-10 not only exhibited a 5- to 10-fold stronger antitumor activity in the sub-μM range against CML cells than S1g-2 in vitro, but it also overcame BCR-ABL-independent tyrosine kinase inhibitor resistance in CML in vivo depending on the HSP70-Bim signaling pathway. Moreover, through structure-activity relationship analysis, TROSY-HSQC NMR, molecular dynamics simulation, and point mutation validation, two hydrophobic pockets composed of eight key residues were demonstrated to produce predominant interactions with either Bim or S1g-10, regarded as the "hot-spots" in the HSP70-Bim PPI interface.

Products